Here are five things to know:
1. Three brokers rated the company a “Buy” and one rated a “Sell,” bringing the consensus to “Buy”
2. The company’s average 12-month price among covering brokers is $29.33 in the last year.
3. Piper Jaffray analysts reiterated an “overweight” rating and set a price target of $29 in a note on Friday.
4. Zacks analysts downgraded K2M shares at the end of May from “hold” to “sell.”
5. The company traded up today, hitting $24.74 and has a market cap of $981.06 million.
More articles on orthopedic devices:
BioMedical Enterprises launches nitinol bone fixation implant
DePuy Orthopaedics issues Class 2 recall for femoral implants
Boston Scientific launches Precision Novi SCS in Europe
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
